drugset / Trial / NCT01546896

Effects of Buspar on Depressive Symptom Improvement and Neuroprotection in Patients With Anxiety Disorder

NCT01546896

RandomizedParallel-groupSingle-blindTreatment

Summary

This research aims to investigate the efficacy and safety of buspirone in treating generalized anxiety disorder with depressive symptoms and to evaluate its neuroprotective effects using magnetic resonance imaging.

Timeline

Start
2012-03
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Alprazolam Small molecule 0.5 mg
Subject Buspirone Small molecule 20 mg
Subject Buspirone Small molecule 30 mg

Indications